SNDX-5613

Research use only, not for human use.

SNDX-5613 is a potent and specific inhibitor of Menin-MLL(Ki of 0.149 nM and a cell based IC50 of 10-20 nM).

SNDX-5613 is a potent and specific inhibitor of Menin-MLL(Ki of 0.149 nM and a cell based IC50 of 10-20 nM). SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias. (In Vivo):Revumenib (SNDX-5613) shows in vivo plasma IC50 of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.

——

Revumenib (SNDX-5613) shows in vivo plasma IC50 of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.

——

Chromatin/Epigenetic

Histone Demethylase

Menin-MLL

——

——

2169919-21-3

630.82

C32H47FN6O4S

>98% (HPLC)

DMSO:41.67 mg/mL (66.06 mM; Need ultrasonic)

O=C(C1=CC(F)=CC=C1OC2=CN=CN=C2N3CC4(C3)CCN(CC4)C[C@H]5CC[C@@H](CC5)NS(=O)(CC)=O)N(C(C)C)CC

——

(-20℃)

With Ice Pack

≥ 2 years